# Medline (MDLN) — Analyst Forecast

MDLN · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/mdln/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 23 | 6 | 0 | 29 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $34.00 | $45.27 | $55.00 | 11 |

Last price $36.57 (as of Oct 16, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 9, 2026 | Barclays | Maintained | Overweight | $43.00 |
| Sep 25, 2026 | UBS | Maintained | Buy | $43.00 |
| Aug 27, 2026 | BTIG | Maintained | Buy | $55.00 |
| Aug 12, 2026 | JP Morgan | Maintained | Overweight | $46.00 |
| Aug 11, 2026 | Wells Fargo | Maintained | Equal-Weight | $34.00 |
| Aug 11, 2026 | Tigress Financial | Maintained | Buy | $55.00 |
| Aug 10, 2026 | TD Cowen | Maintained | Buy | $45.00 |
| Aug 6, 2026 | Stifel | Maintained | Buy | $45.00 |
| Aug 6, 2026 | Evercore ISI Group | Maintained | Outperform | $39.00 |
| Aug 6, 2026 | Truist Securities | Maintained | Buy | $47.00 |
| Aug 6, 2026 | RBC Capital | Maintained | Outperform | $46.00 |
| Jul 31, 2026 | BTIG | Maintained | Buy | $55.00 |
| Jun 3, 2026 | Baird | Maintained | Outperform | $45.00 |
| Jun 1, 2026 | Barclays | Maintained | Overweight | $45.00 |
| May 14, 2026 | BNP Paribas | Maintained | Neutral | $40.00 |
| May 13, 2026 | Tigress Financial | Maintained | Buy | $62.00 |
| May 7, 2026 | BTIG | Maintained | Buy | $55.00 |
| May 7, 2026 | Bernstein | Maintained | Outperform | $54.00 |
| May 7, 2026 | Citigroup | Maintained | Buy | $55.00 |
| Mar 11, 2026 | Citigroup | Maintained | Buy | $60.00 |

## Frequently Asked Questions

### What is the price target for MDLN stock?

The average 12-month analyst price target for Medline (MDLN) is $45.27, with a high estimate of $55.00 and a low of $34.00, across 11 analysts.

### Is MDLN a buy, sell, or hold?

Analysts covering Medline currently average a Buy rating: 23 buy, 6 hold and 0 sell, from 29 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for MDLN?

The average price target of $45.27 implies 23.80% upside from the last price of $36.57.

### What is the latest analyst rating on MDLN?

On Oct 9, 2026, Barclays maintained Medline at Overweight with a price target of $43.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).